ATS 2018 International Conference - Mobile

Revefenacin, a Long-Acting Muscarinic Antagonist (LAMA), Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study [Board No. P1331]

Location: Board no. P1331

Session Type: Thematic Poster Session

Monday

May

21

11:15 AM

1:00 PM

Speaker(s)/Author(s)

Chris N. Barnes

PhD
Theravance Biopharma US, Inc

Marie Borin

PhD
Theravance Biopharma US, Inc

David Bourdet

PhD
Theravance Biopharma US, Inc

Borje Darpo

PhD, MD
iCardiac Thechnologies

Srikanth Pendyala

MD
Theravance Biopharma US, Inc

View Abstract

Revefenacin, a Long-Acting Muscarinic Antagonist (LAMA), Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study

Parent Sessions

B33 - COPD: MAINTENANCE THERAPY
05-21-2018 9:15 AM - 4:15 PM